Miron Fayngersh, MD
Pain Management · Brooklyn, NYNPI 1902918279
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 45.7% of the total. Reporting peaked in 2021 at $366 and has fallen 59.0% since, to $150 in 2024.
Across 32 payments — averaging $35.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$520
- Amgen$222
- Redhill Biopharma Inc.$111
- Kowa Pharmaceuticals America, Inc.$81
- Scilex Pharmaceuticals Inc.$42
- Forte Bio-pharma LLC$35
- plus $127 from 6 others
What the payments were for
- Food & beverage$1,138100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $520 |
| Amgen(2 entities) | 5 | $222 |
| Redhill Biopharma Inc. | 6 | $111 |
| Kowa Pharmaceuticals America, Inc. | 4 | $81 |
| Scilex Pharmaceuticals Inc. | 2 | $42 |
| Forte Bio-pharma LLC | 1 | $35 |
| Sentynl Therapeutics, Inc. | 2 | $33 |
| Indivior Inc. | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| AstraZeneca | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pain management providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 202 | $32,611 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $16,475 |
| Lidocaine | 136 | $12,600 |
| Coreg CrCarvedilol Phosphate | 11 | $10,539 |
| LinzessLinaclotide | 20 | $10,107 |
| LidodermLidocaine | 11 | $8,799 |
| CreonLipase/Protease/Amylase | 18 | $7,920 |
| VascepaIcosapent Ethyl | 23 | $7,063 |
| MovantikNaloxegol Oxalate | 15 | $5,710 |
| BenicarOlmesartan Medoxomil | 14 | $5,219 |
| Metaxalone | 12 | $4,848 |
| Oxycodone Hcl | 234 | $4,797 |
| PrevacidLansoprazole | 12 | $4,453 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 195 | $3,834 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 144 | $2,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $520 | $18,02738 claims |
| Redhill Biopharma Inc.Movantik | $111 | $5,71015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain management providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other pain management in Brooklyn
- Luguang YangBrooklyn$283
- Jennice RileyBrooklyn$28
- Joseph ParkBrooklyn$17
- Igor OstrovskyBrooklyn$0
- Yekatrina SlukhinskyBrooklyn$0
- Steven PinskyRockville Centre$15K
- Evan ChernoffStony Brook$1K
- Nancy ScheinRocky Point$589
- Leslie KaoBronxville$52
- Theresa MitchelFlushing$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.